Natera Dec 21, 2022 Natera Files Second Patent Infringement Suit Against NeoGenomics Subsidiary Inivata Nov 2, 2022 Natera Awarded Contract to Provide Cancer Testing Services to VA Jul 22, 2022 In Brief This Week: Oryzon Genomics, Byondis, Caris Life Sciences, Natera Mar 9, 2022 Natera Minimal Residual Disease Test Value Called Into Question by City of Hope CRC Patient Data Jan 11, 2022 JP Morgan Healthcare Conference Day 1: Novartis, Gilead, Johnson & Johnson, EQRx, Mirati, and More Oct 28, 2021 BGI Genomics Program Seeks to Validate Signatera Test for Colorectal Cancer Patients in China Premium Oct 15, 2021 Natera Builds Data Backing Serial ctDNA Changes to Aid CRC Patient Management, Treatment Decisions Premium Sep 8, 2021 Natera Signatera Test to be Used in Study of MRD-Guided Treatment for Colon Cancer Patients Jul 22, 2021 Natera Minimal Residual Disease Test Predicts Oligometastatic CRC Patient Outcomes in New Study Premium Jul 20, 2021 UK Group Validating Natera ctDNA Test to Guide Therapy for Post-Operative Bladder Cancer Premium Jun 18, 2021 In Brief This Week: Bayer, Saga Diagnostics, Inteliquet, NeoGenomics, Natera May 28, 2021 Guardant Health Sues Natera for False Advertising, 'Misleading' Oncologists About MRD Tests Mar 26, 2021 In Brief This Week: Mirati Therapeutics, Gilead, Natera, Actinium Pharmaceuticals, Myriad Genetics Mar 10, 2021 Genentech Begins Phase III Study of Tecentriq in MRD-Positive Bladder Cancer Feb 26, 2021 Natera Launches Tumor Genomic Profiling Assay, Expects Reproductive Health to Break Even This Year Premium Feb 26, 2021 Elicio Therapeutics Sharpens Development Plan for Cancer Vaccine in KRAS-Mutated Tumors Premium Feb 17, 2021 Natera, Personalis Team up for Cancer Treatment Monitoring, MRD Testing Feb 8, 2021 Strata Oncology Launches Large Study Eyeing Competitive Cancer Monitoring, Drug Selection Test Space Premium Jan 20, 2021 Natera Sues Inivata, Alleging Infringement of Cancer Testing Patents Jan 13, 2021 JP Morgan Healthcare, Day 2: Eli Lilly, Pfizer, GlaxoSmithKline, Clovis Oncology, Invitae, and More Load More Breaking News Apollomics Completes SPAC Merger, Begins Public Trading on Nasdaq Ablaze Pharmaceuticals to Develop RayzeBio's GPC3-Targeted Radiotherapy In Brief This Week: Allarity Therapeutics, Immutep, Thermo Fisher Scientific EMA's CHMP Recommends BMS's Breyanzi as Second-Line Lymphoma Treatment Exai Bio, Quantum Leap Healthcare Collaborative Expand Participation in RNA Liquid Biopsy Trial Omega Therapeutics, Roche Partner for Phase I/II Trial in MYC-Driven Hepatocellular Carcinoma
